Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Merkel cell polyomavirus Oncogenic Network

Project description

Understanding Merkel cell carcinoma tumourigenesis

The EU-funded MONET project aims to provide an understanding of Merkel cell carcinoma (MCC) tumourigenesis. MCC is an aggressive neuroendocrine skin cancer detected in several thousand patients every year in Europe. Merkel cell polyomavirus (MCPyV) is a six-protein encoding system, expressing two proteins with reported oncogenic functions. This limited proteome size allows a system-wide study of the associated oncogenic mechanisms. The researchers will identify the critical interactions of viral and host proteins in MCC oncogenesis using NOD scid mice cell line-derived xenografts and validate MCPyV host proteins drug targeting to combat MCC. The project will underpin translational research and future steps for therapeutic development.

Objective

The aim of the MONET project (Merkel cell polyomavirus Oncogenic Network) is to provide a state-of-the-art understanding of Merkel cell carcinoma (MCC) tumorigenesis. Viral pathogens are estimated to be responsible of ~12% of cancers worldwide and represent useful models for the study of oncogenesis mechanisms. Merkel Cell Carcinoma (MCC) is an aggressive neuroendocrine skin cancer detected in ~2500 patients per year in Europe and has recently been linked with a clonal integration of the Merkel Cell polyomavirus (MCPyV) in more than 80% of cases. MCPyV is a 6-protein encoding system, expressing only two proteins with reported oncogenic functions. This limited proteome size thus allows system-wide study of its associated oncogenic mechanisms. This multi-pronged project consists of: (i) identifying the critical interactions of viral and host proteins in MCC oncogenesis; and (ii), using NOD scid mice cell line derived xenografts (CDXs), validate MCPyV host-proteins drug targeting strategies to combat MCC tumorigenesis. Using cutting-edge mass spectrometry-based techniques combined with CRISPR interference approaches in relevant human cancer cell systems, these studies will uncover new protein-protein interactions essential for tumorigenesis. MCPyV+ MCC CDXs will be used to establish the functional relevance of novel virus-host protein interactions and to assess the therapeutic potential of targeting these host interactors as anti-cancer strategies. The application of these proteomic and functional approaches will allow for a better understanding of MCPyV-associated carcinogenesis. In a broader view, it will define a new framework for identifying druggable targets in pathogen-driven cancers. This project will underpin future translational researches, and hence appears as a fundamental step for therapeutic development.

Fields of science

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 57 646,05
Address
RUE DE TOLBIAC 101
75654 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
€ 57 646,06

Participants (1)